Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model
Status:
RECRUITING
Trial end date:
2027-05-31
Target enrollment:
Participant gender:
Summary
Primary liver cancer is one of the most common malignant tumors in the world, and about 80%\~90% of primary liver cancers are pathologically characterized as hepatocellular carcinoma (HCC). Radical surgery is the main method for patients with HCC to obtain long-term survival. However, the early recurrence rate of high-risk HCC is very high, which seriously affects the overall therapeutic effect.